Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
34.34
+0.46 (1.36%)
At close: Sep 16, 2025, 4:00 PM EDT
34.50
+0.16 (0.47%)
After-hours: Sep 16, 2025, 6:22 PM EDT
Legend Biotech Revenue
Legend Biotech had revenue of $255.06M in the quarter ending June 30, 2025, with 36.74% growth. This brings the company's revenue in the last twelve months to $796.84M, up 74.75% year-over-year. In the year 2024, Legend Biotech had annual revenue of $627.24M with 119.97% growth.
Revenue (ttm)
$796.84M
Revenue Growth
+74.75%
P/S Ratio
7.81
Revenue / Employee
$305,419
Employees
2,609
Market Cap
6.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 627.24M | 342.10M | 119.97% |
Dec 31, 2023 | 285.14M | 168.14M | 143.70% |
Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
Dec 31, 2020 | 75.00M | 13.20M | 21.36% |
Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LEGN News
- 6 days ago - Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Legend Biotech Appoints Carlos Santos as Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade - Seeking Alpha
- 5 weeks ago - Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights - GlobeNewsWire
- 3 months ago - Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting - GlobeNewsWire
- 4 months ago - Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT - GlobeNewsWire
- 4 months ago - Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript - Seeking Alpha